ストックスクリーナーアプリを入手
34.29
2.63%
0.88
アフターアワーズ：
34.00
-0.29
-0.85%
前日終値:
$33.41
開ける：
$34.32
24時間の取引高:
411.99K
Relative Volume:
1.55
時価総額：
$983.32M
収益：
-
当期純損益:
$-38.95M
株価収益率:
-23.08
EPS:
-1.4857
ネットキャッシュフロー:
$-50.43M
1週間 パフォーマンス:
+5.65%
1か月 パフォーマンス:
+20.19%
6か月 パフォーマンス:
+63.36%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$33.17
$34.88
1週間の範囲:
$31.60
$34.88
52週間の値動き範囲:
$13.36
$34.88
Lb Pharmaceuticals Inc Stock (LBRX) Company Profile
Compare LBRX vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LBRX
Lb Pharmaceuticals Inc
|
34.29 | 958.09M | 0 | -38.95M | -50.43M | -1.4857 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.93 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.50 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lb Pharmaceuticals Inc Stock (LBRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-27 | 開始されました | H.C. Wainwright | Buy |
| 2026-04-10 | 開始されました | Craig Hallum | Buy |
| 2026-01-09 | 開始されました | Roth Capital | Buy |
| 2025-10-06 | 開始されました | Leerink Partners | Outperform |
| 2025-10-06 | 開始されました | Piper Sandler | Overweight |
| 2025-10-06 | 開始されました | Stifel | Buy |
すべてを表示
Lb Pharmaceuticals Inc (LBRX) 最新ニュース
LBRX Initiated Coverage by Wolfe Research -- Rating Set to Outpe - GuruFocus
Wolfe Research initiates LB Pharmaceuticals stock with outperform rating By Investing.com - Investing.com India
LB Pharmaceuticals Inc (LBRX) Gains 4.83% as Stock Approaches Resistance at $35.10Early Entry Signals - dars.gov.et
LBRXLB Pharmaceuticals Inc Dividends - Finviz
LB Pharmaceuticals Inc. (LBRX) Maintains Buy Rating as Analyst Highlights LB-102 Potential - Yahoo Finance
5 Best Up and Coming Pharmaceutical Stocks to Buy Now - Insider Monkey
LB Pharmaceuticals names Christopher Zergebel as SVP By Investing.com - Investing.com South Africa
LB Pharmaceuticals names Christopher Zergebel as SVP - Investing.com
LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations - GlobeNewswire
Total assets of LB Pharmaceuticals Inc – NASDAQ:LBRX - TradingView
LB Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:LBRX) - TradingView
LBRX Forecast — Price Target — Prediction for 2027 - TradingView
LB Pharmaceuticals stock rating maintained at buy by H.C. Wainwright - Investing.com
LB Pharmaceuticals Inc (LBRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
LB Pharmaceuticals Inc (LBRX) Institutional Confidence - TradingKey
LB Pharmaceuticals Inc (LBRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
LB Pharmaceuticals Inc (LBRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
LB Pharmaceuticals Inc (LBRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
LB Pharmaceuticals Inc (LBRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
LB Pharmaceuticals Inc (LBRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
LB Pharmaceuticals Inc (LBRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
LB Pharmaceuticals Inc (LBRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
LB Pharmaceuticals Inc (LBRX) Edges Lower Amidst Tight Trading RangeVolatility Stop - newsline.com
LBRX Q1 2026 Earnings: Narrower Loss Surpasses Estimates as Pre-Revenue Biotech Tightens SpendingFinal Results - newsline.com
LB Pharmaceuticals (NASDAQ: LBRX) supplements prospectus after CMO transition - Stock Titan
LB Pharmaceuticals Inc Announces Resignation of Anna Eramo as Chief Medical Officer, Effective June 15, 2026 - marketscreener.com
[8-K] LB PHARMACEUTICALS INC Reports Material Event - Stock Titan
[144] LB PHARMACEUTICALS INC SEC Filing - Stock Titan
LB Pharmaceuticals Stockholders Approve Directors and Auditor - TipRanks
LB Pharmaceuticals (NASDAQ: LBRX) elects board and ratifies auditor in 2026 - Stock Titan
LB Pharmaceuticals (NASDAQ: LBRX) investors back board slate and ratify BDO as 2026 auditor - Stock Titan
LBRX Options Volatility — NASDAQ:LBRX - TradingView
LB Pharmaceuticals Inc (LBRX) Shows Modest Uptick as Stock Holds Above Key SupportPut Spread Alert - newsline.com
LBRX Q1 2026 Earnings: EPS Beat Estimates as Biotech Advances PipelineEarnings Quality Score - newsline.com
LB Pharmaceuticals (LBRX) Slips 1.28% as Stock Holds Above Key Support — What's Next?Reversal Trade - newsline.com
LB Pharmaceuticals (LBRX) grants director 10,000 stock options at $27.95 - Stock Titan
LB Pharmaceuticals (LBRX) awards 10,000 options to director vesting in 2027 - Stock Titan
[Form 4] LB PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
LB Pharmaceuticals (LBRX) director receives 12,500 stock options at $27.95 strike - Stock Titan
LB Pharmaceuticals (LBRX) director receives 10,000 stock options at $27.95 strike - Stock Titan
Director at LB Pharmaceuticals (LBRX) receives grant of 10,000 stock options at $27.95 - Stock Titan
LB Pharmaceuticals (LBRX) director awarded 10,000 stock options at $27.95 - Stock Titan
LB Pharmaceuticals (LBRX) AGM 2026 Summary - Quartr
LBRX: All proposals passed, electing directors and ratifying the auditor for 2026 - TradingView
LB Pharmaceuticals Inc (LBRX) Q1 2026 Earnings: EPS Surprise on Lower-Than-Expected LossOperating Income Trends - newsline.com
LB Pharmaceuticals (LBRX) Q1 2026 Earnings: EPS Surprise Signals Improving Operational DisciplineBook Value Growth - newsline.com
LBRX News Today | Why did LB Pharmaceuticals stock go up today? - MarketBeat
Schizophrenia drug developer LB Pharmaceuticals heads to June investor talks - Stock Titan
LBRX Options Chain — NASDAQ:LBRX - TradingView
Top LB Pharmaceuticals (LBRX) Competitors 2026 - MarketBeat
Bipolar Depression Market Poised for Robust Growth with Upcoming Novel Therapies and Improved Diagnostics - Barchart.com
Lb Pharmaceuticals Inc (LBRX) 財務データ
収益
当期純利益
現金流量
EPS
Lb Pharmaceuticals Inc (LBRX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Deep Track Biotechnology Maste | 10% Owner |
Sep 12 '25 |
Buy |
15.00 |
2,000,000 |
30,000,000 |
2,686,138 |
| Deep Track Biotechnology Maste | 10% Owner |
Sep 12 '25 |
Buy |
15.00 |
666,666 |
9,999,990 |
666,666 |
| Pontifax Management 4 G.P. (20 | 10% Owner |
Sep 12 '25 |
Buy |
15.00 |
1,000,000 |
15,000,000 |
1,411,681 |
| Nussbaum Ran | Director |
Sep 12 '25 |
Buy |
15.00 |
1,000,000 |
15,000,000 |
1,411,681 |
| Vida Ventures GP III, L.L.C. | 10% Owner |
Sep 12 '25 |
Buy |
15.00 |
333,333 |
4,999,995 |
880,214 |
1.18%
2.48%
大文字化:
|
ボリューム (24 時間):